Literature DB >> 11581529

Neurosarcoidosis.

Aljoeson Walker1, William Tyor.   

Abstract

Neurosarcoidosis is an uncommon disorder and requires a careful clinical evaluation to reach a diagnosis. Generally, patients with peripheral symptoms, which include paresthesias, painful patches over extremities, and stocking glove deficits, have a better outcome when compared with those with central nervous system (CNS) involvement. Patients with mass lesions or hydrocephalus tend to have more relapses and are often more resistant to routine therapy. Neurosarcoidosis often responds to glucocorticoids, usually within days or weeks of initiating therapy. Patients are usually maintained on 40 to 80 mg per day for 4 to 6 weeks, then tapered slowly. The use of alternative treatments for refractory neurosarcoidosis, or to reduce or eliminate steroids, includes methotrexate, cyclophosphamide, azathioprine, cyclosporine, chlorambucil, chloroquine, and hydroxychloroquine.

Entities:  

Year:  2001        PMID: 11581529     DOI: 10.1007/s11940-001-0015-8

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  23 in total

1.  Determination of angiotensin-converting enzyme levels in cerebrospinal fluid is not a useful test for the diagnosis of neurosarcoidosis.

Authors:  J C Dale; J F O'Brien
Journal:  Mayo Clin Proc       Date:  1999-05       Impact factor: 7.616

Review 2.  Neuro-ophthalmic complications of sarcoidosis.

Authors:  T Constantino; K Digre; P Zimmerman
Journal:  Semin Neurol       Date:  2000       Impact factor: 3.420

Review 3.  Neurosarcoidosis: progress and clinical aspects.

Authors:  T F Scott
Journal:  Neurology       Date:  1993-01       Impact factor: 9.910

4.  Epidemiology of familial sarcoidosis in the UK.

Authors:  D S McGrath; Z Daniil; P Foley; J L du Bois; P A Lympany; P Cullinan; R M du Bois
Journal:  Thorax       Date:  2000-09       Impact factor: 9.139

5.  Central nervous system sarcoidosis: follow-up at MR imaging during steroid therapy.

Authors:  J L Dumas; D Valeyre; C Chapelon-Abric; C Belin; J C Piette; H Tandjaoui-Lambiotte; M Brauner; D Goldlust
Journal:  Radiology       Date:  2000-02       Impact factor: 11.105

Review 6.  Extensive leptomeningeal and intraparenchymatous spinal cord neurosarcoidosis.

Authors:  A A Castellano-Sánchez
Journal:  South Med J       Date:  2000-08       Impact factor: 0.954

7.  Neurosarcoidosis with unusual MRI findings.

Authors:  M S Handler; L M Johnson; A R Dick; S Batnitzky
Journal:  Neuroradiology       Date:  1993       Impact factor: 2.804

8.  Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group.

Authors:  H L Weiner; G A Mackin; E J Orav; D A Hafler; D M Dawson; Y LaPierre; R Herndon; J R Lehrich; S L Hauser; A Turel
Journal:  Neurology       Date:  1993-05       Impact factor: 9.910

9.  Effectiveness of chloroquine and hydroxychloroquine in treating selected patients with sarcoidosis with neurological involvement.

Authors:  O P Sharma
Journal:  Arch Neurol       Date:  1998-09

10.  Neurosarcoidosis: cerebrospinal fluid lymphocyte subpopulations.

Authors:  B J Stern; D E Griffin; R A Luke; A Krumholz; C J Johns
Journal:  Neurology       Date:  1987-05       Impact factor: 9.910

View more
  1 in total

Review 1.  Nanoscale drug delivery systems and the blood-brain barrier.

Authors:  Renad Alyautdin; Igor Khalin; Mohd Ismail Nafeeza; Muhammad Huzaimi Haron; Dmitry Kuznetsov
Journal:  Int J Nanomedicine       Date:  2014-02-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.